A case series examining the efficacy of gabapentin as a substitution therapy for the treatment of pregabalin use disorder
The American Journal of Drug and Alcohol Abuse · 2025
DOI: 10.1080/00952990.2025.2467458 ↗Kurz gefasst
Fallbericht in der Zeitschrift The American Journal of Drug and Alcohol Abuse, 2025. Verfasst von Olivier Lejeune und 3 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hépatologie et d'Addictologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France. Hauptthemen laut MEDLINE: Pregabalin, gamma-Aminobutyric Acid, Amines, Substance-Related Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
Gabapentinoids are ligands of a brain calcium channel, which are approved for different indications, including epilepsy, neuropathic pain, or generalized anxiety disorder. Among gabapentinoids, pregabalin has been increasingly associated with a risk of pregabalin use disorder (PUD). To date, there is no recommended medical treatment for PUD. However, gabapentin, which has a lower abuse potential, could be used as a substitution therapy to reduce pregabalin withdrawal and craving.
Objectives
To report on the experimental use of high dose of gabapentin among those with PUD.
Methods
Case series of four patients (3 males and 1 female) with severe PUD (average daily doses ranging from 1,200 to 8,400 mg of pregabalin), in whom high dose of gabapentin was prescribed as a substitution treatment.
Results
Upon gabapentin being administered as substitution therapy for pregabalin, all four patients experienced intense craving and distress. Despite receiving high doses of gabapentin, due to the observed levels of craving and distress, all four patients had to be rapidly switched back to pregabalin.
Conclusions
Preliminary clinical findings suggest that gabapentin is unlikely to be a suitable, lower-risk alternative treatment for people with PUD. Additional examination of candidate medications, including other gabapentinoids, could be useful to identify an effective treatment for PUD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service d'Hépatologie et d'Addictologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
- Service Universitaire d'Addictologie de Lyon (SUAL), Hospices Civils de Lyon, Lyon, France.
- Service Pharmaceutique, Hospices Civils de Lyon, Lyon, France.
- Service Universitaire d'Addictologie de Lyon (SUAL), Pôle MOPHA, CH le Vinatier, Bron, France.
- PSYR2, CRNL, Université Claude Bernard Lyon 1, INSERM U1028, CNRS UMR5292, Bron, France.
ORCID-Profile: Mathieu Chappuy, Benjamin Rolland
Zitieren
APA
Lejeune, O., Chappuy, M., Bailly, F., & Rolland, B. (2025). A case series examining the efficacy of gabapentin as a substitution therapy for the treatment of pregabalin use disorder. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.1080/00952990.2025.2467458
Vancouver
Lejeune O, Chappuy M, Bailly F, Rolland B. A case series examining the efficacy of gabapentin as a substitution therapy for the treatment of pregabalin use disorder. The American Journal of Drug and Alcohol Abuse. 2025. doi:10.1080/00952990.2025.2467458
BibTeX
@article{Lejeune2025,
author = {Lejeune, Olivier and Chappuy, Mathieu and Bailly, François and Rolland, Benjamin},
title = {A case series examining the efficacy of gabapentin as a substitution therapy for the treatment of pregabalin use disorder},
journal = {The American Journal of Drug and Alcohol Abuse},
year = {2025},
doi = {10.1080/00952990.2025.2467458}
}
EUVIMED